TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00810199
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Approximately 15-17 mg methotrexate capsule orally once a week.
Study: NCT00810199
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching methotrexate capsule taken orally once a week.
Study: NCT01966172
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral ibuprofen 400mg 4 times daily
Study: NCT04312243
Drug: Inhaled nitric oxide gas
Normalized name: nitric oxide / nitrogen Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
Study: NCT01789788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, multiple doses
Study: NCT01789788
Drug: RO6811135
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending doses
Study: NCT01967589
Drug: NNC0113-0987
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
Study: NCT01967589
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily doses for oral administration
Study: NCT01121939
Drug: Sandostatin LAR® Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
Study: NCT00914134
Drug: Levodopa infusion
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
Study: NCT01441128
Drug: PF-02341066/PF-00299804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined PF-02341066 and PF-00299804
Study: NCT02291289
Drug: 5-FU/LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
Study: NCT02291289
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
Study: NCT01441128
Drug: PF-02341066/PF-00299804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
Study: NCT00650221
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 80 mg immediate-release oral tablet
Study: NCT00650221
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose 80 mg immediate-release tablet
Study: NCT01137253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response to intrabrachial vasodilators during IV saline infusion
Study: NCT00002822
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002822
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01106131
Drug: CKD-501 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
Study: NCT00661089
Drug: Placebo (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
Study: NCT04322032
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.
Study: NCT04322032
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
Study: NCT05186129
Drug: Clopid® 75 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
Study: NCT05186129
Drug: Plavix® 75mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
Study: NCT02038179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
Study: NCT02056418
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
Study: NCT04361422
Drug: Isotretinoin Only Product in Oral Dose Form
Normalized name: Isotretinoin only product in oral dose form
Approvals — FDA: no, EMA: no, PMDA: no
Description: assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
Study: NCT01209403
Drug: Glucose-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv infusion of glucose
Study: NCT01209403
Drug: Glucose-insulin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous iv infusion of glucose and shortlasting
Study: NCT00687908
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel to the face, once daily in the evening for 24 weeks.
Study: NCT03003247
Drug: IDP-120 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-120 Gel is a combination product
Study: NCT03003247
Drug: IDP 120 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03576638
Drug: Accordion Pill Carbidopa/Levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP 50/500 TID days 2-7
Study: NCT03576638
Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet
Normalized name: Sinemet CR 25mg-100mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25/100 1.5 pills five times/day
Study: NCT00300222
Drug: NGX-4010
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04202497
Drug: [18F]MNI-1054 (radiotracer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]MNI-1054 injection.
Study: NCT03627013
Drug: Custodiol-N Solution
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion
Study: NCT03627013
Drug: Custodiol HTK Solution
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion
Study: NCT02097173
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04351724
Drug: Thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: as local standard, most likely to be low molecular weight heparin
Study: NCT00030654
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00802646
Drug: fentanyl/bupivacaine/epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
Study: NCT01655225
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally. Dose of 20 to 600 mg, as determined in Part A.
Study: NCT01145664
Drug: Herbal concentrate-granules plus western therapy
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Study: NCT01145664
Drug: Western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Study: NCT00955799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind treatment period of 29 weeks placebo
Study: NCT01483638
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be administered orally with the same schedule of axitinib
Study: NCT01348724
Drug: [14C] NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 25 mg oral dose administered on Day 1
Study: NCT06312800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
Study: NCT03812900
Drug: Echinacea purpurea alcoholic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
Study: NCT00254865
Drug: EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02134093
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous pump infusion normal saline with identical volume of dexmedetomidine.
Study: NCT00293059
Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
Study: NCT00293059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be taken orally daily.
Study: NCT02134093
Drug: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
Study: NCT02627196
Drug: Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01660867
Drug: 3% saline + oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
Study: NCT02949349
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 5 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 5 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 10 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 20 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 30 mg AZD3965 OD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 30 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 15 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment.~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT01791595
Drug: AZD3965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day -7: single dose of 20 mg AZD3965 orally prior to start of continuous treatment (first 3 trial participants in the Expansion Cohort only; subsequent patients started treatment at Cycle 1, Day 1).~Cycle 1, Day 1: commenced dosing of 10 mg AZD3965 BD orally for up to 6 28-day cycles.~Trial participants benefitting from treatment could continue beyond 6 cycles for as long as they continued to benefit on agreement between the Investigator and the Sponsor.
Study: NCT02949349
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose not more than 10mg, orally, for 24 weeks.
Study: NCT03294694
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
Study: NCT04602494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Study: NCT03844776
Drug: Co-Amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin + clavulanic acid orally
Study: NCT00338767
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication treatment includes flouxetine for treatment of depression.
Study: NCT03428568
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT03289390
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
Study: NCT00029393
Drug: Immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03844776
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline irrigation
Study: NCT01623921
Drug: standard care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study: NCT01623921
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study: NCT01623921
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study: NCT01699724
Drug: JZoloft
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablet on Day 1 of each period
Study: NCT01919164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Placebo matched to sprifermin as intra-articular injection.
Study: NCT03338881
Drug: [14C]-TAK-659
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-TAK-659 solution.
Study: NCT00062595
Drug: phylloquinone (K1)
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02100839
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline for injection
Study: NCT00018824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079480
Drug: Placebo matching with BMS-986090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04094168
Drug: DEL NIDO CARDIOPLEGIA
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq.
Study: NCT04094168
Drug: COLD BLOOD BASED CARDIOPLEGIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
Study: NCT00104182
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04787887
Drug: EU-sourced Cerezyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60IU/kg Single Intravenous Administration
Study: NCT00649636
Drug: Fluoxetine Capsules 40 mg
Normalized name: fluoxetine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, single dose fasting
Study: NCT01463917
Drug: Hypertonic solution
Normalized name: Hypertonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
Study: NCT01463917
Drug: Isotonic
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
Study: NCT00664352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site.
Study: NCT01557478
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Study: NCT01557478
Drug: match placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
Study: NCT03569098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators will inject the reconstituted solution into foot muscles.
Study: NCT02007317
Drug: Oshadi D & Oshadi R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti tumor agents
Study: NCT00478270
Drug: ibandronate [Bondronat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg iv on days 1-3
Study: NCT03337815
Drug: Treatment of MTX and TwHF placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
Study: NCT03337815
Drug: Treatment of TwHF and MTX placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Study: NCT00001322
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Estradiol, 100mcg/day by skin patch
Study: NCT00001322
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository twice daily
Study: NCT00001322
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by skin patch
Study: NCT00129441
Drug: Merck L-830982
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
Study: NCT00129441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
Study: NCT01897337
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.